Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5987404 | 1.00 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6152342 | 1.00 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6152345 | 1.00 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6153257 | 0.85 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6152388 | 0.85 | NPC1 (0.58) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL5987676 | 0.85 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6153018 | 0.85 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL6152740 | 0.85 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL5986977 | 0.85 | CHRNA7 (0.52) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL5988428 | 0.85 | NPC1 (0.58) | CHRNA7CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| JP-2003514818-A | — | — | 2003-04-22 | — | — | JP | claimed |
| EP-1233964-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2002-08-28 | — | — | EP | claimed |
| WO-2001036417-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | claimed |
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | disclosed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050165057-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1500648-A1 | NOVEL PIPERIDINE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6683090-B1 | N-(1-AZABICYCLO(2.2.2)OCT-3-YL)PROPENAMIDE DERIVATIVES; PSYCHOTIC AND INTELLECTUAL IMPAIRMENT DISORDERS | ASTRAZENECA AB (SE) | 2004-01-27 | — | — | US | disclosed |
| EP-1233964-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001036417-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNA7 46/4885CHRM2 121/4885CHRM1 411/4885 |
| US-20050165057-A1 | Novel piperidine derivative | ACAT2, ACAT1, LCAT | CHRNA7 3248/4885CHRM2 699/4885CHRM1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.